4D pharma plc

4D is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease.  4D has developed a sector-leading discovery platform, MicroRx, that rationally identifies bacterial drug candidates based on a deep understanding of function and mechanism.  4D's Live Biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut.  4D has clinical stage candidates in Oncology (including a clinical collaboration with MSD/Merck & Co.), Respiratory and Gastrointestinal disease, and a strong pre-clinical pipeline with programs in Oncology, CNS, and Autoimmune/Inflammatory disease; in addition we have an ongoing research collaboration with MSD (Merck & Co.) utilizing the MicroRx platform to discover and develop LBPs for vaccines. AIM: 'DDDD' NASDAQ: 'LBPS', expected Q1 2021